Intensity Therapeutics Announced A Business Update Reflecting Progress In Its Phase 3 Sarcoma Clinical Program; FDA Provided “Study May Proceed Letter” For Phase 3 Within 30 Day Period Following IND Submission
IND Submission for Phase 3In the fourth quarter of 2023, the Company submitted a new Investigational New Drug ("IND") to the Food and Drug Administration ("FDA"). The submission included the phase 3 protocol for a